LUKMANAFIS BABAJIDE: Open Payments
NPI 1134657067 · RANCHO MIRAGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,982 in 54 payments from 14 companies in 2025. Trend: 2023 $436 · 2024 $4,051 · 2025 $2,982
Food & beverage: $2,873Education: $109
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $1,157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $336 |
| Axsome Therapeutics, Inc. | 5 | $231 |
| E.R. Squibb & Sons, L.L.C. | 4 | $218 |
| ABBVIE INC. | 7 | $188 |
| Otsuka America Pharmaceutical, Inc. | 3 | $174 |
| Vanda Pharmaceuticals Inc. | 9 | $167 |
| Alkermes, Inc. | 2 | $153 |
| Teva Pharmaceuticals USA, Inc. | 2 | $147 |
| Supernus Pharmaceuticals, Inc. | 3 | $80 |
Products named: INVEGA SUSTENNA, SPRAVATO, CAPLYTA, Auvelity, REXULTI, VRAYLAR, FANAPT, ARISTADA.
Industry payments across CA — which companies pay providers there.
